Table 1.

HRs for recurrence of breast cancer in the model used to compare initial use of an aromatase inhibitor with sequencing in hormone receptor–positive postmenopausal women (16)

Trial (AI)HR
ER+/PR+ER+/PR−All ER+
Initial AI vs tamoxifen
    ATAC (anastrozole)0.840.430.74
    BIG 1-98 (letrozole)0.72*0.72*0.72
Sequencing AI vs tamoxifen
    ARNO 95/ABCSG 8 (anastrozole)0.650.420.60
    ITA (anastrozole)0.36
    IES (exemestane)0.720.630.70
Extended AI vs placebo
    MA-17 (letrozole)0.57
    ABCSG 6a0.64
  • Abbreviations: IA, aromatase inhibitor; ITA, Italian Tamoxifen Arimidex trial; ARNO, Arimidex-Nolvadex; ABCSG, Austrian Breast and Colorectal Cancer Study Group.

  • * Approximate value based on similar disease-free survival.

  • Approximate based on disease-free survival values of 0.66 versus 0.58 in an earlier analysis.